Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S
Record ID 32010000247
English
Authors' recommendations:
Although economic analyses are subject to considerable uncertainty, the study supports recent NICE clinical guidelines that NPH should be the preferred first line choice of insulin in type 2 diabetes. This finding is driven by much the higher costs and limited clinical advantage of the comparators long acting insulin analogues glargine and detemir. Exenatide appeared clinically and cost effective as an alternative to starting insulin immediately on failure of oral therapy for glucose lowering. Sitagliptin and vildagliptin had similar clinical effectiveness as glitazone but this was achieved at lower cost and side effects
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1743
Year Published:
2010
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Blood Glucose
- Decision Making
- Practice Guidelines as Topic
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
- Insulin
- Peptides
- Thiazolidinediones
- Exenatide
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2010 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.